Exelixis
Logotype for Exelixis Inc

Exelixis (EXEL) investor relations material

Exelixis Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Exelixis Inc
Jefferies Global Healthcare Conference summary18 Nov, 2026

Strategic transition and execution

  • Transitioning from a CABO-centered business toward multiple products and franchises, with Zanza development, commercial execution, early pipeline progress and disciplined expense management as priorities.

  • Long-term goal: build a business with multiple products and labels across RCC, NET and CRC, extending the franchise-building approach used with CABO.

  • CABO revenue and the planned Zanza launch support investment across internal R&D, external opportunities and share buybacks; these priorities are not viewed as mutually exclusive.

Capital allocation and R&D priorities

  • Annual R&D budget targeted at a cap of ~ $1B; plan is to keep expenses flat as revenue grows, supporting earnings growth and investment flexibility.

  • Programs are prioritized by evidence, biology, vision and commercial opportunity; franchises are assessed for potential to lead across multiple products and indications.

  • Financial flexibility also leaves room to pursue external opportunities when attractive, while maintaining deliberate expense management.

Zanza development and differentiation

  • Zanza was designed to retain CABO-like kinase activity while using a shorter half-life to make dose holds, reductions and symptom resolution more manageable, particularly in combination regimens.

  • Differing tissue distribution may reduce hand-foot syndrome burden; the profile supports evaluating activity and combinations across tumor types in wave one and wave two.

  • Seven pivotal studies are underway; management said randomized survival trials are needed to determine whether early efficacy signals translate into survival benefit.

  • Zanza studies are designed individually around dose, combination and patient population; efficacy, safety and secondary endpoints all influence commercial adoption.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Exelixis earnings date

Logotype for Exelixis Inc
Q4 20269 Feb, 2027
Exelixis
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Exelixis earnings date

Logotype for Exelixis Inc
Q4 20269 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Exelixis Inc is a biotechnology company focused on developing and commercializing small molecule therapies for cancer treatment. The company engages in drug discovery, clinical development, and partnerships targeting multiple oncology indications. The company is headquartered in Alameda, California, and its shares are listed on the NASDAQ.